Treatment to Target Using Recombinant Interleukin‐1 Receptor Antagonist as First‐Line Monotherapy in New‐Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five‐Year Follow‐Up Study-Reference-Cited by-同舟云学术

Treatment to Target Using Recombinant Interleukin‐1 Receptor Antagonist as First‐Line Monotherapy in New‐Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five‐Year Follow‐Up Study

Published:2019-05-25 Issue:7 Volume:71 Page:1163-1173
ISSN:2326-5191
Container-title:Arthritis & Rheumatology
language:en
Short-container-title:Arthritis Rheumatol

Author:

ter Haar Nienke M.¹,Dijkhuizen E. H. Pieter¹,Swart Joost F.¹,Royen‐Kerkhof Annet¹,el Idrissi Ayman²,Leek Arjen P.²,Jager Wilco¹,Groot Mark C. H.¹,Haitjema Saskia¹,Holzinger Dirk³,Foell Dirk⁴,Loosdregt Jorg¹,Wulffraat Nico M.¹,Roock Sytze¹,Vastert Sebastiaan J.¹

Affiliation:

1. University Medical Center Utrecht and Utrecht University Utrecht The Netherlands

2. Utrecht University Utrecht The Netherlands

3. University of Munster, Munster, Germany, and University of Duisburg‐Essen Essen Germany

4. University of Duisburg‐Essen Essen Germany

Funder

FP7 Health

Publisher

Wiley

Subject

Immunology,Rheumatology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.40865

Reference40 articles.

1. Systemic JIA: new developments in the understanding of the pathophysiology and therapy

2. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001;Petty RE;J Rheumatol,2004

3. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis

4. Practice and consensus-based strategies in diagnosing and managing systemic juvenile idiopathic arthritis in Germany

5. Application of the Yamaguchi criteria for classification of “suspected” systemic juvenile idiopathic arthritis (sJIA)

Cited by 129 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The epigenetic determinants for systemic juvenile idiopathic arthritis phenotyping and treatment response;BMC Musculoskeletal Disorders;2024-08-06

2. Anakinra as first-line monotherapy for new-onset steroid-naïve sJIA patients;Expert Review of Clinical Immunology;2024-07-30

3. A quantitative comparison between the essential medicines for rheumatic diseases in children and young people in Africa and the WHO model list;Pediatric Rheumatology;2024-07-04

4. Tailoring the treatment of inflammatory rheumatic diseases by a better stratification and characterization of the clinical patient heterogeneity. Findings from a systematic literature review and experts' consensus;Autoimmunity Reviews;2024-07

5. Therapeutic potential of the topical recombinant human interleukin-1 receptor antagonist in guinea pigs with allergic rhinitis;Allergy, Asthma & Clinical Immunology;2024-06-04